Skip to main
PASG

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio Inc is focused on developing innovative gene therapies for neurodegenerative diseases, and recent modifications to the trial protocol for PBFT02 may enable earlier intervention, potentially leading to enhanced patient outcomes. The company's valuation suggests room for growth, particularly if it secures regulatory alignment for accelerated approval based on biomarker endpoints, which could shorten trial durations and enhance the speed of bringing therapies to market. Additionally, the faster enrollment strategy in Cohort 3 could expedite trial progress, positioning Passage Bio favorably in a competitive landscape for genetic medicines targeting these critical conditions.

Bears say

Passage Bio Inc faces significant challenges that contribute to a negative outlook on its stock. The company's early-stage gene therapy programs are susceptible to delays and safety concerns, particularly surrounding immune reactions, which could adversely affect market sentiment and lead to downward revisions of estimates. Furthermore, the complexities associated with manufacturing AAV-based gene therapy products pose an additional risk, as insufficient production capabilities could constrain the company's forecasts and hinder its development timelines.

PASSAGE BIO (PASG) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Strong Buy based on their latest research and market trends.

According to 5 analysts, PASSAGE BIO (PASG) has a Strong Buy consensus rating as of Apr 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.